Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a price target of $35.
December 19, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer reaffirmed an Overweight rating on Longboard Pharmaceuticals with a steady price target of $35.
The reiteration of an Overweight rating by a reputable analyst firm like Cantor Fitzgerald typically instills confidence in investors and can have a positive impact on the stock price in the short term. The maintenance of a high price target ($35) compared to the current trading price suggests significant upside potential, which can also contribute to positive investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100